LakeShore Biopharma Shareholders Approve Merger, Paving Way to Go Private

LakeShore Biopharma Co., Ltd (OTCPK: LSBCF; OTCPK: LSBWF) announced on June 19, 2026, that its shareholders have voted to approve the merger agreement that will result in the company becoming privately held. The extraordinary general meeting (EGM) saw approximately 92.3% of the company’s outstanding ordinary shares voted, with about 86.2% of votes cast in favor of the proposal.

The merger agreement, originally dated November 4, 2025, and amended on April 29, 2026, involves LakeShore Biopharma, Oceanpine Skyline Inc. (Parent), and Oceanpine Merger Sub Inc. (Merger Sub). Under the terms, Merger Sub will merge with and into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Parent. Following the merger, the company’s shares and warrants will no longer be listed on any public marketplace, including the OTC Pink tier, and will cease to be registered under the Securities Exchange Act of 1934.

The approval marks a significant step toward the company’s transition from a public to a private entity. Completion of the merger remains subject to the satisfaction or waiver of conditions outlined in the agreement. LakeShore Biopharma stated it will work with the other parties to finalize the transaction in due course.

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics for infectious diseases and cancer. Its proprietary PIKA® immunomodulating technology platform underpins a range of preventive and therapeutic biologics targeting rabies, hepatitis B, influenza, and other viral infections. The company operates in China, Singapore, and the Philippines.

The decision to go private has implications for the company’s future strategy. As a private entity, LakeShore Biopharma will no longer be subject to the quarterly reporting requirements and public scrutiny that come with a stock exchange listing. This could allow management to focus on long-term goals without the pressure of short-term market expectations. However, it also means that existing public shareholders will lose the ability to trade shares on open markets.

Forward-looking statements in the press release highlight risks and uncertainties, including the possibility that the merger may not occur as planned if termination events arise or if financing is unavailable. The company also noted that various closing conditions may not be satisfied or waived. These factors could affect the timing and completion of the merger.

For more information about LakeShore Biopharma, visit its investor relations page at https://investors.lakeshorebio.com/. The original press release is available at www.newmediawire.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is LakeShore Biopharma Shareholders Approve Merger, Paving Way to Go Private.

The post LakeShore Biopharma Shareholders Approve Merger, Paving Way to Go Private appeared first on citybuzz.